EUVIMEDEUVIMED entdecken
Crossref

Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa

Sergio López-Manzaneda iD, Ángeles Mencía iD, José Bonafont iD, Alex Bassons-Bascuñana iD, Marta García iD, Alexander Nyström iD, Blanca Duarte iD, Sara Llames iD, Rodolfo Murillas iD, Silvia Modamio-Hoybjor iD, Matías Morín iD, Lucía Soletto iD und 4 weitere

Human Gene Therapy · 2025

DOI: 10.1089/hum.2024.238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Sergio López-Manzaneda und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Innovation CIEMAT-CIBERER, Madrid, Spain. Hauptthemen laut MEDLINE: Collagen Type VII, Epidermolysis Bullosa Dystrophica, Exons, Gene Editing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations leading to premature termination codons in COL7A1 are commonly associated with severe generalized recessive dystrophic epidermolysis bullosa (RDEB). Previous research, including our own, has indicated that removing mutated COL7A1 exons along with the consequent reframing of COL7A1 may not pose noticeable impact on protein function, offering a potential therapeutic strategy. However, investigations into the long-term in vivo effects of genome editing-mediated removal of mutant exons have only focused on the small exon 80 thus far. Hence, this study focuses on exons 73 and 105 of COL7A1 to explore whether targeted exon removal, through a CRISPR/Cas9-assisted, Non-homologous end joining (NHEJ)-mediated approach, could be extended to other larger exons. Introducing ribonucleoprotein complexes carrying Cas9 and optimized sgRNA guide pairs for each exon (73 and 105) through electroporation efficiently led to their removal, consequently restoring type VII collagen (C7) synthesis in RDEB primary patient cells carrying frameshift mutations in these exons. In vitro tests indicated the normal stability of the resulting C7 variants expressed at physiological levels, while in vivo analyses of regenerated skin grafted onto immunodeficient mice using E73 or E105 RDEB edited cells demonstrated the proper deposition of C7 at the basement membrane zone, thereby restoring normal dermo-epidermal adherence. This study enhances the broader potential of the exon deletion approach in the treatment of RDEB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Collagen Type VIIEpidermolysis Bullosa DystrophicaExonsGene EditingGenetic TherapyHumansAnimalsCRISPR-Cas SystemsMiceDNA End-Joining Repair

Stichwörter der Autor:innen

Crispr/Cas9epidermolysis bullosagene reframinggenodermatosesgenome editing

Substanzen

Collagen Type VIICOL7A1 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Innovation CIEMAT-CIBERER, Madrid, Spain.
  • Instituto de Investigacion Sanitaria. Fundación Jimenez Díaz, Madrid, Spain.
  • Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
  • Department of Bioengineering, University Carlos III Madrid (UC3M), Madrid, Spain.
  • Department of Dermatology, Medical Center-University Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute of Medical and Molecular Genetics (INGEMM), IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.

ORCID-Profile: Sergio López-Manzaneda, Ángeles Mencía, José Bonafont, Alex Bassons-Bascuñana, Marta García, Alexander Nyström, Blanca Duarte, Sara Llames, Rodolfo Murillas, Silvia Modamio-Hoybjor, Matías Morín, Lucía Soletto, María J Escamez, Miguel A Moreno-Pelayo, Marcela Del Rio, Fernando Larcher

Zitieren

APA

López-Manzaneda, S., Mencía, Á., Bonafont, J., Bassons-Bascuñana, A., García, M., Nyström, A., Duarte, B., Llames, S., Murillas, R., Modamio-Hoybjor, S., Morín, M., Soletto, L., Escamez, M. J., Moreno-Pelayo, M. A., Rio, M. D., & Larcher, F. (2025). Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa. Human Gene Therapy. https://doi.org/10.1089/hum.2024.238

Vancouver

López-Manzaneda S, Mencía Á, Bonafont J, Bassons-Bascuñana A, García M, Nyström A, et al. Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa. Human Gene Therapy. 2025. doi:10.1089/hum.2024.238

BibTeX
@article{LpezManzaneda2025,
  author = {López-Manzaneda, Sergio and Mencía, Ángeles and Bonafont, José and Bassons-Bascuñana, Alex and García, Marta and Nyström, Alexander and Duarte, Blanca and Llames, Sara and Murillas, Rodolfo and Modamio-Hoybjor, Silvia and Morín, Matías and Soletto, Lucía and Escamez, María J and Moreno-Pelayo, Miguel A and Rio, Marcela Del and Larcher, Fernando},
  title = {Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa},
  journal = {Human Gene Therapy},
  year = {2025},
  doi = {10.1089/hum.2024.238}
}
Kostenlos starten →